☆ 4.6 Review

DNA damage repair mutations in pancreatic cancer- prognostic or predictive?

FRONTIERS IN ONCOLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

Precision Medicine for BRCA/PALB2-Mutated Pancreatic Cancer and Emerging Strategies to Improve Therapeutic Responses to PARP Inhibition

Daniel R. Principe

Summary: For a small subset of pancreatic ductal adenocarcinoma (PDAC) patients with loss-of-function mutations in BRCA1/2 or PALB2, first-line and maintenance therapy differ significantly due to the loss of double-strand break DNA homologous recombination (HR). Current treatment guidelines emphasize specific strategies for PDAC tumors deficient in HR, along with emerging approaches to improve drug responses.

CANCERS (2022)

Add to Collection

Article Medicine, General & Internal

Prevalence of Germline Sequence Variations Among Patients With Pancreatic Cancer in China

Lingdi Yin et al.

Summary: A higher incidence of pancreatic cancer has been reported in the Chinese population compared with the White population, and genetic background of pancreatic cancer in the Han Chinese population with PDAC was explored in this study, revealing a significant association between pathogenic germline variations and sporadic pancreatic cancer in China.

JAMA NETWORK OPEN (2022)

Add to Collection

Review Biochemistry & Molecular Biology

Beyond BRCA: The Emerging Significance of DNA Damage Response and Personalized Treatment in Pancreatic and Prostate Cancer Patients

Bruna Dalmasso et al.

Summary: The BRCA1/2 genes play a crucial role in breast, ovarian, pancreatic and prostate cancers. Other genes involved in homologous recombination and DNA damage response are being studied as potential targets for treatment. However, these genes are not routinely tested worldwide. This study summarizes the genetic and cellular burden of these genes and suggests that including DDR genes shared by both pancreatic and prostate cancers can lead to better detection of actionable variants.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Add to Collection

Article Oncology

Association of Pathogenic Variants in Hereditary Cancer Genes With Multiple Diseases

Chenjie Zeng et al.

Summary: This study utilized large datasets from three cohorts to identify associations between hereditary cancer genes and various phenotypes, highlighting the potential benefits of early detection and better management of cancer.

JAMA ONCOLOGY (2022)

Add to Collection

Article Oncology

Platinum-based chemotherapy for pancreatic cancer: impact of mutations in the homologous recombination repair and Fanconi anemia genes

Marina Emelyanova et al.

Summary: This study aimed to evaluate the frequency of mutations in homologous recombination (HR) and Fanconi anemia (FA) genes related to pancreatic cancer (PC) and their clinical implications for platinum-based chemotherapy. The results showed that mutations in BRCA1/2 and PALB2 genes increased the sensitivity of PC to platinum agents. The prognostic value of these gene mutations was not observed in early-stage PC patients.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer

Stephan B. Dreyer et al.

Summary: DDR deficiency and replication stress are independent of each other, offering opportunities for therapy in DDR-proficient PC and after platinum therapy. Patient-derived cell lines faithfully recapitulate the epithelial component of pancreatic tumors, including previously described molecular subtypes, and serve as a valuable model for studying novel therapeutic strategies targeting DDR and replication stress in PC.

GASTROENTEROLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives

Lukas Perkhofer et al.

Summary: Complex rearrangement patterns and mitotic errors are characteristics of most PDAC, caused by DNA double-strand breaks and defective DNA repair pathways. DSB repair pathways, such as HR, play a crucial role in maintaining genomic integrity, and deficiencies in DDR pathways like BRCA1 and BRCA2 are common in both inherited and sporadic PDAC, leading to potential vulnerabilities to new therapeutic interventions. The POLO trial with olaparib showed promising results in PDAC patients with germline BRCA1/2 mutations, suggesting a potential for improved outcomes in this subgroup.

GUT (2021)

Add to Collection

Article Gastroenterology & Hepatology

Synergistic targeting and resistance to PARP inhibition in DNA damage repair-deficient pancreatic cancer

Johann Gout et al.

Summary: The study identified synergistic effects in inhibiting PARP, ATR, and DNA-PKcs that lead to synthetic lethality in ATM-deficient pancreatic ductal adenocarcinoma. Chemical inhibition of ATM sensitized human PDAC cells towards this combinatorial therapy, which was also found to overcome PARP inhibitor resistance. These findings suggest potential mutation-specific therapeutic strategies that may be applied through ATM inhibition regardless of genotype.

GUT (2021)

Add to Collection

Article Oncology

Homologous recombination repair deficiency (HRD): From biology to clinical exploitation

David Gonzalez et al.

GENES CHROMOSOMES & CANCER (2021)

Add to Collection

Article Oncology

Clinical Significance of Germline Cancer Predisposing Variants in Unselected Patients with Pancreatic Adenocarcinoma

Elena Fountzilas et al.

Summary: Limited data exists on the prognostic and predictive value of germline cancer predisposing pathogenic/likely pathogenic variants (P/LPVs) in patients with pancreatic ductal adenocarcinoma. This study examined germline testing of 62 cancer susceptibility genes in 549 unselected patients with pancreatic cancer, revealing a significant proportion of patients carrying P/LPVs in clinically relevant genes. While the presence of any P/LPVs was associated with improved overall survival, its independent prognostic significance was not retained in multivariate analysis, and P/LPVs in homologous recombination repair genes did not predict benefit from platinum-based treatment. The results suggest the need for further validation through universal genetic testing and consideration of newer treatments for patients with pancreatic cancer.

CANCERS (2021)

Add to Collection

Review Cell Biology

DNA Damage Repair Deficiency in Pancreatic Ductal Adenocarcinoma: Preclinical Models and Clinical Perspectives

Jojanneke Stoof et al.

Summary: Pancreatic ductal adenocarcinoma (PDAC) is a deadly cancer with DDR deficiency playing an important role in its pathogenesis, yet understanding of these mechanisms is limited. The lack of appropriate laboratory experimental models poses a challenge to preclinical research, despite the potential for high predictivity and effective clinical translation when models effectively recapitulate the original cancer.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)

Add to Collection

Review Medicine, General & Internal

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

Matthew J. Page et al.

Summary: The PRISMA statement was designed to help systematic reviewers transparently report the purpose, methods, and findings of their reviews. The updated PRISMA 2020 statement includes new reporting guidance, a 27-item checklist, an abstract checklist, and revised flow diagrams for reviews.

BMJ-BRITISH MEDICAL JOURNAL (2021)

Add to Collection

Review Oncology

Targeting DNA damage repair pathways in pancreas cancer

Fionnuala Crowley et al.

Summary: Pancreas ductal adenocarcinoma (PDAC) is the third leading cause of cancer death in the USA, with a stagnant 5-year survival rate despite new targeted therapies. Recent studies show that PDAC is a heterogeneous disease with actionable mutations in some patients who can benefit from targeted therapies.

CANCER AND METASTASIS REVIEWS (2021)

Add to Collection

Review Oncology

Hereditary pancreatic cancer

Kodai Abe et al.

Summary: Pancreatic cancer is associated with both family and hereditary cancer syndromes. Multigene panel testing for pancreatic cancer can detect high-risk genes, and active surveillance is recommended for high-risk individuals. PARP inhibitor therapy is currently being applied to pancreatic cancer patients harboring BRCA1/2 germline variants.

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Review Medicine, General & Internal

Pancreatic Cancer: A Review

Wungki Park et al.

Summary: Pancreatic ductal adenocarcinoma (PDAC) is a relatively uncommon cancer with increasing incidence each year, resulting in a high percentage of patients being diagnosed with advanced disease. Current cytotoxic therapies for PDAC are moderately effective, emphasizing the importance of multidisciplinary management, comprehensive germline testing, and integrated supportive care for all patients.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Review Oncology

Homologous Recombination Deficiency in Pancreatic Cancer: A Systematic Review and Prevalence Meta-Analysis

Raffaella Casolino et al.

Summary: The study analyzed the prevalence of HRD in PDAC patients, finding that surrogate markers of HRD identified more patients than gene-level approaches. There is a need to harmonize HRD definitions and validate the optimal biomarker for treatment selection. Universal HRD screening, including integrated somatic and germline analysis, should be offered to all PDAC patients.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Medicine, Research & Experimental

The germline/somatic DNA damage repair gene mutations modulate the therapeutic response in Chinese patients with advanced pancreatic ductal adenocarcinoma

Lin Shui et al.

Summary: In this retrospective study, the role of germline and somatic DDR mutations in predicting the efficacy of olaparib and platinum-based chemotherapy in Chinese PDAC patients was shown. The DDR mutation was found to be an independent prognostic factor for survival analysis of advanced PDAC patients. Further investigation is needed to determine the value of DDR mutation in predicting hypermutation status and sensitivity to PD-1 blockade.

JOURNAL OF TRANSLATIONAL MEDICINE (2021)

Add to Collection

Review Gastroenterology & Hepatology

The pancreatic cancer genome revisited

Akimasa Hayashi et al.

Summary: Pancreatic cancer is a genetic disease characterized by recurrent genetic alterations. Major roles have been identified for genetic alterations in complex systems such as SWI/SNF and COMPASS, as well as copy number alterations in genes like GATA6 and MYC. Developments in germline variants, mismatch repair deficiencies, and homologous recombination deficiencies highlight the shift towards precision medicine in pancreatic cancer research.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2021)

Add to Collection

Review Gastroenterology & Hepatology

Pancreatic cancer in 2021: What you need to know to win

Valeria Tonini et al.

Summary: Pancreatic cancer has a poor prognosis, with a less than 10% five-year survival rate. Surgical resection is the only potentially curative treatment, but the tumor is often diagnosed late in the disease process and surgery is limited. Post-operative morbidity is high, and other therapies offer disappointing results.

WORLD JOURNAL OF GASTROENTEROLOGY (2021)

Add to Collection

Letter Gastroenterology & Hepatology

DNA Damage Repair Defects and Survival Outcomes for Patients With Resected Pancreatic Ductal Adenocarcinoma

Amy E. Chang et al.

PANCREAS (2021)

Add to Collection

Article Oncology

Clinical Characteristics of Patients With Pancreatic Cancer and Pathogenic ATM Alterations

Zain Hannan et al.

Summary: The study identified and profiled 22 patients with PDAC and ATM alterations, showing a significantly longer median overall survival for patients with ATM alterations compared to those without, suggesting that pathogenic ATM alterations may improve outcomes in pancreatic cancer patients.

JNCI CANCER SPECTRUM (2021)

Add to Collection

Article Oncology

Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation

Max M. Wattenberg et al.

BRITISH JOURNAL OF CANCER (2020)

Add to Collection

Article Oncology

Germline DNA Sequencing Reveals Novel Mutations Predictive of Overall Survival in a Cohort of Patients with Pancreatic Cancer

Jennifer B. Goldstein et al.

CLINICAL CANCER RESEARCH (2020)

Add to Collection

Article Oncology

Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial

Michael J. Pishvaian et al.

LANCET ONCOLOGY (2020)

Add to Collection

Review Biochemistry & Molecular Biology

PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications

Heng Zhu et al.

MOLECULAR CANCER (2020)

Add to Collection

Article Oncology

Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection

Wungki Park et al.

CLINICAL CANCER RESEARCH (2020)

Add to Collection

Review Oncology

Synthetic lethality strategies: Beyond BRCA1/2 mutations in pancreatic cancer

Yunlong Hu et al.

CANCER SCIENCE (2020)

Add to Collection

Article Surgery

Association of Germline Variants in Human DNA Damage Repair Genes and Response to Adjuvant Chemotherapy in Resected Pancreatic Ductal Adenocarcinoma

Haijie Hu et al.

JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2020)

Add to Collection

Article Oncology

Effect of Germline Mutations in Homologous Recombination Repair Genes on Overall Survival of Patients with Pancreatic Adenocarcinoma

Siddhartha Yadav et al.

CLINICAL CANCER RESEARCH (2020)

Add to Collection

Review Oncology

Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma

Yunzhen Qian et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)

Add to Collection

Article Multidisciplinary Sciences

Pan-cancer landscape of homologous recombination deficiency

Luan Nguyen et al.

NATURE COMMUNICATIONS (2020)

Add to Collection

Article Genetics & Heredity

Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer

Matthew B. Yurgelun et al.

GENETICS IN MEDICINE (2019)

Add to Collection

Article Oncology

DNA damage repair deficiency as a predictive biomarker for FOLFIRINOX efficacy in metastatic pancreatic cancer

Sofia Palacio et al.

JOURNAL OF GASTROINTESTINAL ONCOLOGY (2019)

Add to Collection

Article Oncology

Retrospective Survival Analysis of Patients With Resected Pancreatic Ductal Adenocarcinoma and a Germline BRCA or PALB2 Mutation

Shun Yu et al.

JCO PRECISION ONCOLOGY (2019)

Add to Collection

Article Oncology

Treatment and survival rates of stage IV pancreatic cancer at VA hospitals: a nation-wide study

Ibrahim Azar et al.

JOURNAL OF GASTROINTESTINAL ONCOLOGY (2019)

Add to Collection

Article Surgery

BRCA1/BRCA2 Germline Mutation Carriers and Sporadic Pancreatic Ductal Adenocarcinoma

Alex B. Blair et al.

JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2018)

Add to Collection

Article

Association between homologous recombination repair gene mutations and response to oxaliplatin in pancreatic cancer

Tomohiro Kondo et al.

Oncotarget (2018)

Add to Collection

Article Oncology

Retrospective Survival Analysis of Patients With Advanced Pancreatic Ductal Adenocarcinoma and Germline BRCA or PALB2 Mutations

Kim A. Reiss et al.

JCO PRECISION ONCOLOGY (2018)

Add to Collection

Article Oncology

Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX

Amikar Sehdev et al.

CLINICAL CANCER RESEARCH (2018)

Add to Collection

Article Oncology

Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer

Talia Golan et al.

BRITISH JOURNAL OF CANCER (2017)

Add to Collection

Article Oncology

Having Pancreatic Cancer with Tumoral Loss of ATM and Normal TP53 Protein Expression Is Associated with a Poorer Prognosis

Haeryoung Kim et al.

CLINICAL CANCER RESEARCH (2014)

Add to Collection

Editorial Material Public, Environmental & Occupational Health

Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses

Andreas Stang

EUROPEAN JOURNAL OF EPIDEMIOLOGY (2010)

Add to Collection

© Peeref 2019-2024. All rights reserved.